Ravulizumab

Complement terminal pathway inhibition

Ravulizumab (C5 inhibitor) — Dermatomyositis

• Trial: NCT04999020 (Phase 2/3)
• MOA: blocks C5 → prevents terminal complement activation (MAC formation).
• Public results: no definitive efficacy readout published for DM yet; trial remains the key public source for status/endpoints.
• Sponsor/developer: Alexion Pharmaceuticals (within _{AstraZeneca}_).